Dr Reddy’s Labs announces commercial launch of 2-DG
June 28, 2021
Dr Reddy’s Laboratories has announced the commercial launch of 2-deoxy-D-glucose (2-DG), a drug for moderate to severe Covid-19 patients administered as an adjunct therapy to the existing standard care.
The emergency use approval for anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.
Dr Reddy’s will supply to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.
2-DG manufactured by Dr Reddy’s has a purity of 99.5 per cent and is being sold commercially under the brand name 2-DG. The maximum retail price (MRP) of each sachet has been fixed at ₹990, with a subsidised rate offered to government institutions.